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In South Africa (SA), excellent gains have been 
made since 2002 in prevention of mother-to-child 
transmission (PMTCT) of HIV, with >90% of HIV-
infected women accessing PMTCT.[1] The national 
early transmission rate of HIV infection at around 6 
weeks of age is measured by the District Health Information System, 
the National Health Laboratory Service and the 2010 - 2013 South 
African PMTCT Evaluation (SAPMTCTE) studies and is on track to 
meet the National Strategic Plan target of <2% in 2015.[2-4] To detect 
postnatal transmission of HIV, national guidelines recommend that 
HIV-exposed uninfected (HEU) infants undergo repeat HIV testing 
6 weeks after weaning and at 18 months of age. With dwindling 
early vertical transmission rates as a result of SA’s successful PMTCT 
programme, proportionately more infants and children diagnosed 
after 6 weeks of age will contribute to the paediatric HIV epidemic, 
and it is vital that they are identified.
HIV testing after weaning and at 18 months is poorly implemented 
and monitored, with post-weaning HIV testing being particularly 
problematic because in practice it lacks a specific time point. Exclusive 
breastfeeding for the first 6 months of life under antiretroviral therapy 
(ART) cover for HIV-exposed infants has been recommended in SA 
since 2010, with continued breastfeeding to 12 months of age.[5] After 
the 6-week HIV polymerase chain reaction (PCR) test, no HIV test 
is scheduled for a period of 1 year for the majority of breastfed HEU 
infants at daily risk of postnatal transmission, unless they are weaned 
earlier or become symptomatic. Coverage of 18-month testing for 
HEU infants is also poor and data from programmatic settings are 
scarce. Grimwood et al.[6] of Kheth’Impilo report HIV positivity rates 
in children tested at 18 months of 10.7% in 2009, reduced to 3.8% 
in 2011; however, only 24% of HIV-exposed children were tested. 
The rate of postnatal transmission and the extent of the paediatric 
HIV epidemic in SA therefore remain unmeasured and HIV-infected 
infants and children remain unidentified. 
Factors that increase the risk of postnatal transmission are maternal 
infections not diagnosed during pregnancy, infection acquired late 
in pregnancy or during breastfeeding, poor adherence to ART 
during breastfeeding, and mixed infant feeding practices.[7,8] Exclusive 
breastfeeding rates are low, with the SAPMTCTE reporting rates of 
35.5% at 6 weeks in 2010.[4] Furthermore, there is mounting evidence 
that the 6-week HIV PCR test yields false-negative results in the 
presence of maternal and/or infant antiretroviral prophylaxis.[9] These 
infants are likely to be diagnosed later in life, with their infection 
attributed to postnatal transmission. 
A new routinely offered and provider-initiated testing strategy is 
required in SA to ensure testing of infants exposed to HIV through 
breastmilk and those who are missed in the first few months of 
life. Since 2008, World Health Organization (WHO) guidelines 
for infant HIV diagnosis have recommended using an antibody 
detection assay such as an HIV rapid test (HRT) at 9 months of age 
for all HEU infants, with a confirmatory HIV PCR test if the HRT 
is positive.[10]  HRTs performed on whole blood are able to detect 
seroreversion (the loss of maternal HIV antibodies) in the majority 
of HEU infants by 8 - 10 months of age, depending on the HRT 
used.[11] This means that a carefully selected HRT routinely offered 
at the 9-month Expanded Programme on Immunization (EPI) visit 
could exclude HIV infection in 80 - 100% of HEU infants. Measles 
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Background. South Africa (SA) is likely to meet the National Strategic Plan target of <2% mother-to-child HIV transmission at 6 weeks 
of age in 2015. Children infected with HIV after 6 weeks often remain undiagnosed because of poor implementation of post-weaning and 
final outcome 18-month HIV testing. The World Health Organization recommends a screening HIV rapid test (HRT) in HIV-exposed 
infants at the 9-month immunisation visit to exclude postnatal infection, with a confirmatory HIV polymerase chain reaction (PCR) test 
if the HRT is positive.
Objective. To evaluate the impact of substituting this recommendation for the post-weaning HIV testing recommended by SA guidelines.
Methods. Rates of seroreversion and probability of infection at 9 months of age were applied to a theoretical population of 100 HIV-exposed 
infants, uninfected at birth and breastfed for 1 year with antiretroviral prophylaxis. Nine scenarios were developed and the number of HIV 
PCRs saved compared with current guidelines was calculated.
Results. Nine-month testing using the HRT reduced the number of follow-up PCR tests done in all scenarios by >50%, with differences 
ranging from 51% to 59% and 81% to 89% for low and high seroreversion rates, respectively.
Conclusions. Nine-month testing using HRT would increase identification and early treatment of HIV-infected infants, improve 
monitoring of postnatal transmission rates, and reduce the number of HIV PCR tests done with resultant cost saving. Training of healthcare 
workers implementing HRT would be required. Ongoing efforts to improve implementation and monitoring of testing at 9 and 18 months 
will be essential. 
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coverage rates at 9 months (MCV1) in SA 
in 2010 were reported to be 95%, higher 
than the 83% in the same year of the second 
measles vaccine (MCV2), suggesting that 
if 9-month HRT were introduced at the 
9-month measles vaccine visit, coverage 
of HIV-exposed infants might potentially 
be greater than at the 18-month visit. [12] 
The vast burden of testing costs in an 
infant HIV testing programme lies in the 
number of HIV PCR tests performed, 
costing between ten and 30 times more 
than any HRT used in SA (Prof. Gayle 
Sherman, personal communication). An 
inexpensive screening test that coincides 
with a routine (EPI) visit at 9 months 
will diagnose HIV-infected infants early 
at a routine visit, provide data to monitor 
transmission at 9 months and plan for the 
numbers of children requiring combination 
antiretroviral therapy (cART), facilitate 
initiation of cART to prevent morbidity and 
mortality, and assist with identifying gaps 
in prevention programmes. Additionally, 
performing HRT will reduce the costs 
associated with the more expensive HIV 
PCR test, which will be unnecessary in 
infants testing HIV-negative on HRT. 
Objective 
To evaluate the impact of introducing a 
screening HRT test for HEU infants 
at the routine 9-month EPI visit for 
measles immunisation in line with WHO 
recommendations, with a confirmatory HIV 
PCR test for infants testing positive on HRT, 
instead of a post-weaning HIV PCR test.
Methods
Estimating the number of HIV PCR 
tests avoided with 9-month HRT
Under current National Department of 
Health (NDoH) guidelines, all infants who 
ever start breastfeeding require one HIV 
PCR test after cessation of breastfeeding 
(assuming they are <18 months of age), 
occurring around 13.5 months of age in 
those breastfed until 12 months. In the 
testing proposed in this article, all infants 
who ever start breastfeeding will be tested 
with a screening HRT at 9 months and a 
confirmatory HIV PCR test if the HRT is 
positive. Only infants who test positive on 
the HRT at 9 months, which would include 
infants who are HIV-infected and those 
who have not yet seroreverted, therefore 
require an HIV PCR test. If an infant is 
HIV-uninfected but still breastfeeding at the 
9-month visit, they would receive a follow-
up HRT at 18 months as per the current 
guidelines unless they became symptomatic 
(Fig. 1).
To directly compare the number of HIV PCR 
tests performed under current guidelines 
with the proposed 9-month HRT testing, 
a model was constructed for a population 
of 100 breastfeeding HEU infants and 
restricted to include only the HIV PCR 
tests performed after weaning and after a 
positive HRT. Breastfeeding exposure was 
assumed to be 100% and to continue to 
12 months of age, as recommended in the 
WHO and NDoH guidelines. The model 
did not include recently introduced targeted 
birth and 16-week testing, the 6-week 
HIV PCR, clinically indicated testing in 
symptomatic children, and testing at or after 
18 months of age, because the numbers of 
these tests would not differ between the 
NDoH guidelines and the proposed testing. 
Nine scenarios were developed that 
factored in a combination of low, middle 
and high levels of both seroreversion and 
the probability of becoming HIV-infected 
over 9 months of breastfeeding.[8,11,13] Ranges 
described in published literature were used 
to determine low, middle and high levels 
of: (i) the rate of seroreversion at 9 months 
of age (~80%, range 60 - 90%)[8] and (ii) the 
probability of infant infection per month of 
HIV-exposed breastfeeding with 0 - 100% 
coverage of infant prophylaxis or maternal 
cART (~0.002, range 0.0016 - 0.01).[8,13] 
Under the nine resulting scenarios, the diff-
erence in the number of PCR tests between 
post-weaning PCR testing and replacement 
of post-weaning testing with 9-month HRT 
screening and PCR confirmatory testing 
was calculated (Table 1). The probability 
of becoming HIV-infected as a result of 
late maternal seroconversion and masked 
intrapartum infection was not taken into 
account by the model. All calculations were 
done using Microsoft Excel.
Results
In a hypothetical population of 100 breast-
feeding HIV-exposed infants, replacing post- 
6 wk
DoH guidelines Proposed algorithm
at any age
9 mo.
18 mo.
6 wk after
weaning
Clinically
indicated
(symptomatic)
•   HIV PCR for all •   HIV PCR for all
•   None
•   HIV Ab test for all •   HIV Ab test for all
•   HIV Ab/PCR combo if
    ever BF exposed
•   None
•   <18 mo.: HIV PCR
•   ≥18 mo.: HIV Ab test
•   <18 mo.: HIV PCR
•   ≥18 mo.: HIV Ab test
•   <9 mo.: HIV PCR
•   ≥9 mo. to <18 mo.: HIV
    Ab/PCR combo
•   ≥18 mo.: HIV Ab test
Fig. 1. Guideline for service delivery models for exposed infant HIV testing. HIV testing by age and timing 
for all HEU infants included in current DoH guidelines and proposed 9-month HRT algorithm. (BF = 
breastfed; Ab = antibody; Ab/PCR combo = Ab test screening, confirmatory PCR if Ab test is positive.)
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weaning PCR testing with 9-month HRT testing reduces the number 
of follow-up PCR tests done in all scenarios by >50%. The differences 
ranged from 51% to 59% with a low seroreversion rate, from 71% to 
79% if the seroreversion rate was middle range, from 81% to 89% 
with a high seroreversion rate, from 59% to 89% with a low monthly 
probability of infection, from 58% to 88% with a middle estimate 
of infection rates, and from 51% to 81% with a high probability 
of infection (Table 1). The number of HIV PCRs done under the 
proposed 9-month HRT testing did not change by a large amount 
with different values for the probability of infection per month of 
breastfeeding, with no more than eight HIV PCR tests saved between 
the low and high estimates, because the main burden of HIV PCR 
tests carried out was for infants who have not seroreverted and 
will need an HIV PCR test to confirm or exclude HIV infection. 
Consequently, the number of HIV PCR tests done was very sensitive 
to the seroreversion rates used, with 30 HIV PCR tests saved between 
the low and high seroreversion estimates (Table 1). 
Discussion
In this hypothetical calculation that sought to evaluate the potential 
impact of integrating HRT into the 9-month routine EPI visit, we 
show that the number of HIV PCR tests can be reduced by >50% 
in all scenarios. This would reduce the costs associated with HIV 
PCR testing and the need for follow-up visits in children testing 
negative with HRT and no longer breastfeeding. Additionally, infants 
infected as a result of breastfeeding, masked intrapartum infection or 
late maternal infection, provided that women are tested 3-monthly 
post partum as recommended in the guidelines, will be diagnosed 
earlier than with the current NDoH guidelines. Currently infants 
infected with HIV postnatally who are breastfeeding at 9 months 
would only be tested 6 weeks after cessation of breastfeeding, if 
symptomatic or at 18 months, resulting in late diagnosis and late 
cART initiation. Considering the low rates of post-cessation and 
18-month HIV testing, it is likely that these children would continue 
for many years without being diagnosed, eventually presenting ill 
and immunocompromised in late childhood or early adolescence.[14] 
Routine testing at 9 months, integrated into the EPI, is more likely 
to be implemented than post-breastfeeding cessation testing that 
may not coincide with EPI visits. It would also allow for collection 
of routine data for monitoring the postnatal transmission rate at 
9 months of age in a breastfeeding population, data that are not 
available programmatically at present. 
Implementation of a 9-month HIV testing strategy requires 
consideration of potential barriers. The strategy requires buy-in from 
EPI nurses, who may be unable or reluctant to include HIV testing 
in the 9-month EPI visit because of the added workload. SA’s routine 
health data sources in 2012/13 demonstrate 94% immunisation 
coverage in the first year of life and 77% at 18 months of age, whereas 
the infant HIV testing rate at 6 weeks was 73% with no routine data 
available for 18-month HIV testing.[2,3] Attendance at routine EPI 
visits therefore does not automatically translate into HIV testing 
at these visits. The emphasis placed on 6-week HIV PCR testing 
dramatically increased coverage from 33% in 2008 to 74% in 2012,[2] 
during which time 18-month HIV testing stagnated. Prioritising 
HIV testing in the maternal and child health programme would be 
required to improve HIV testing rates at 9 and 18 months of age. 
The SA HCT policy recommends provider-initiated counselling 
and testing for children at every contact with a healthcare facility. 
Since breastfed HEU children are at daily risk of HIV transmission, 
there is no harm in using HRT more frequently in infants aged ≥9 
months. HIV testing in a ≥9-month-old child, identified as being 
6 weeks post weaning, is indicated to determine final HIV status 
following maternal HIV exposure. Healthcare workers will also 
require education regarding the different interpretation of the HRT 
results in children <18 months of age, indicating HIV exposure 
if positive and not necessarily HIV infection. The consequences 
of failing to convey this message will result in HEU infants who 
serorevert later than 9 months of age being labelled as HIV-infected 
and initiated on lifelong therapy. 
There are barriers to HIV testing in children that are not 
encountered in adults. A child may be accompanied to EPI visits by 
a caregiver who is not the parent, legal guardian or primary caregiver 
and is unable to provide consent for HIV testing on behalf of the 
child. In a study from Tanzania, children were five times more likely 
to be tested if they were brought to the clinic by a biological HIV-
infected parent.[15] If caregivers want to avoid testing themselves 
and/or their infants, there may be an adverse effect of decreased 
attendance at the 9-month immunisation visit. However, these 
barriers have not been reported in the current PMTCT programme at 
the 6-week visit. The nationally representative SA PMTCT evaluation 
study demonstrated that 97% of infants attending the 6-week EPI visit 
were accompanied by their mothers and caregivers, and there was 
high (94%) acceptance and willingness to undergo HIV testing for 
themselves and their infants.[4] Ongoing monitoring for barriers to 
the 9-month HIV testing strategy will be necessary.
As with any diagnostic test, false-negative results can occur, but the 
risk of failing to identify an HIV-infected infant can be minimised 
by an appropriately validated HRT and conducting concurrent 
clinical examinations.[11] In programme settings, false negatives may 
occur because of incorrect use of the test, such as not waiting the 
recommended time for the true result on HRTs with 15 minutes or 
longer turnaround time. This can be minimised by using an HRT 
with a short turnaround time, which may also increase acceptability 
of the test to staff and clients accessing testing. Sherman et al.[11] have 
shown that Insti HRT is a highly specific test for exclusion of HIV 
infection in this setting, has a 1-minute turnaround time for ease of 
use in a busy EPI clinic, and reduces the time barrier to implementing 
this new intervention in an already overwhelmed system.
Study limitations
This model has limitations. Owing to a lack of local data we assumed 
that women would breastfeed for 12 months as recommended by 
guidelines, but this may be an over- or underestimate, as women 
breastfeed for variable time periods. Maternal refusal of HIV testing 
for themselves and their infants was not factored into the model. 
Infants infected as a result of late maternal seroreversion or masked 
Table 1. Number of HIV PCRs avoided per 100 HIV-exposed 
breastfed infants*
Seroreversion at 9 months
Low (60%) Mid (80%) High (90%)
Probability of 
infection per month of 
breastfeeding
Low (0.0016) 59 79 89
Mid (0.0020) 58 78 88
High (0.0100) 51 71 81
*Using ranges described in published literature for HIV exposed infant seroreversion rates 
at 9 months of age (~80%, range 60 - 90%) and the probability of infant HIV infection per 
month of breastfeeding (~0.002, range 0.0016 - 0.01), the number of follow-up PCRs per 100 
HIV-exposed breastfed infants saved by doing a screening HRT at 9 months compared with 
post-weaning PCR testing, depending on low, medium and high probability of HIV infection 
and low, medium and high rates of seroreversion, is shown.
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intrapartum infections were not included, but given that these 
would be the same in either testing strategy, the reported outcomes 
are unlikely to be affected. We did not model a detailed costing of 
9-month HRT implementation, particularly the cost of training 
healthcare workers, and are only able to make assumptions based on 
the reduction in the number of HIV PCRs required. 
Conclusions
If SA were to adopt the WHO recommendation to test all HEU 
infants at the 9-month EPI visit with an HRT and a confirmatory 
HIV PCR for those testing positive, more HIV-infected infants 
would be identified earlier, with the potential benefit of early cART 
initiation and monitoring of postnatal transmission rates at 9 months 
of age. This model suggests that replacing post-weaning testing with 
9-month HIV testing would save costs for the country in terms 
of HIV tests performed. Training healthcare workers to interpret 
positive HRT results in children <18 months of age is likely to 
increase costs initially. Ongoing efforts would be required to improve 
implementation of testing at 9 and 18 months to determine the extent 
of and properly manage the paediatric HIV epidemic. A multicentre, 
nationwide pilot study would validate these findings and allow for a 
formal cost analysis of the introduction of a 9-month immunisation 
HRT. 
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